Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005

MedGenMed Medscape General Medicine

Volumn 10, Issue 6, 2008, Pages

  Peters Jr , Patrick H ^a   Moscona, Anne ^b   Schulman, Kathy L ^c   Barr, Charles E ^d  

^a National Medical Association   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Thomson Healthcare   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HEALTH INSURANCE; HEART DISEASE; HOSPITALIZATION; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; OTITIS MEDIA; PNEUMONIA; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME; COMPARATIVE STUDY; INFANT; MIDDLE AGED; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; PNEUMONIA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 45849142570     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Abdel-Magid AF, Maryanoff CA, Mehrman SJ. Synthesis of influenza neuraminidase inhibitors. Curr Opin Drug Discov Devel. 2001;4:776-791.
2. Smith NM, Bresee JS, Shay DK, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1-42.
3. Zimmerman RK, Ruben FL, Ahwesh ER. Influenza, influenza vaccine, and amantadine/rimantadine. J Fam Pract. 1997;45:107-122; quiz 23-24.
4. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186.
5. Irwin DE, Weatherby LB, Huang WY, et al. Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res. 2001;1:8.
6. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-1672.
7. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza. recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1-40.
8. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355:827-835.
9. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295:891-894.
10. MMWR. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season. Available at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5502a7.htm. Last accessed May 8, 2008.
11. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240-1246.
12. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-1024.
13. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: randomized controlled trial. JAMA. 2001;285:748-754.
14. Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006;367:303-313.
15. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999;282:31-35.
16. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44(Suppl B):23-29.
17. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-133.
18. Nordstrom BL, Sung I, Suter P, et al. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin. 2005;21:761-768.
19. Kaiser L, Keene ON, Hammond JM, et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med. 2000;160:3234-3240.
20. Kutikova L, Bowman L, Chang S, et al. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. J Neurooncol. 2007;81:61-65.
21. Botteman MF, Ozminkowski RJ, Wang S, et al. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs. 2007;21:319-334.
22. Chang S, Long SR, Kutikova L, et al. Burden of pancreatic cancer and disease progression: economic analysis in the US. Oncology. 2006;70:71-80.
23. Erban JK, Lau J. On the toxicity of chemotherapy for breast cancer-the need for vigilance. J Natl Cancer Inst. 2006;98:1096-1097.
24. Hedrick A Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000;19:410-417.
25. Heckmann JJ, Ichimura H, Todd P. Matching as an Econometric Evaluation Estimator: Evidence from Evaluating a Job Training Programme. Review of Economic Studies. 1997;64:604-654.
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
27. Matheson NJ, Symmonds-Abrahams M, Sheikh A, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev. 2003:CD002744.
28. Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002;185:147-152.
29. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States JAMA 1995, 273: 214-219.
30. Coco AS. Cost-effectiveness analysis of treatment options for acute otitis media. Ann Fam Med. 2007;5:29-38.
31. Fagan HB, Moeller AH. What is the best antiviral agent for influenza infection? Am Fam Physician. 2004;70:1331-1332.
32. Munoz FM. The impact of influenza in children. Semin Pediatr Infect Dis. 2002;13:72-78.
33. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232-239.
34. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225-231.
35. Cooper NJ, Sutton-AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235.
36. IMS Health, IMS National Sales Perspective Database (September 2006 - May 2007). Fairfield, Conn: IMS Health; 2007.
37. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. Clin Infect Dis. 2006;43:564-568.
38. Cox FM, Cobb MM, Chua WQ, et al. Cost of treating influenza in emergency department and hospital settings. Am J Manag Care. 2000;6:205-214.
39. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333-1340.
40. Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis. 2004;39:459-464.
41. Patriarca PA. New options for prevention and control of influenza. JAMA. 1999;282:75-77.
42. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160:3243-3247.
43. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc. 2002;50:608-616.
44. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003;51:123-129.
45. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333.